Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001144204-17-019216
Filing Date
2017-04-05
Accepted
2017-04-05 16:30:16
Documents
2
Period of Report
2017-04-03

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT v463502_3.html 3  
1 OWNERSHIP DOCUMENT v463502_3.xml 3 1653
2 EXHIBIT 24 v463502_ex24.htm EX-24 3069
  Complete submission text file 0001144204-17-019216.txt   6218
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Issuer) CIK: 0000895051 (see all company filings)

EIN.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 200 ROUTE 31 NORTH SUITE 104 FLEMINGTON NJ 08822
Business Address
Zukiwski Alexander A (Reporting) CIK: 0001569782 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-20713 | Film No.: 17742919